In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Authorized Generics: Band-Aid or Strategy?

Executive Summary

In the past two years, some Big Pharma companies have revitalized their long-dormant generics activities and launched generic copies of their own drugs. They're doing this to capture business they would otherwise lose completely and to tie up generics competitors in court. While similar strategies failed in the past, a number of changes may make it more feasible. Innovators are behaving more rationally about pricing. And they are going after the most lucrative part of the generics business.

You may also be interested in...

Generic Plavix: As Bristol Swoons, Broad Implications

The immediate ramifications of Bristol and Sanofi's failed authorized generics strategy around Plavix may cripple Bristol, hobble, Sanofi, and make a mint for Canadian generics player Apotex. But the most significant impact may be felt in the long term along the fault line where branded and generics companies meet, compete, and increasingly, deal.

Mylan's War on Authorized Generics

Changes to the Medicaid law will put a crimp in the economics of "authorized" generic agreements. But Mylan won't be happy until Congress takes further action.

Teva/Ivax: Generics' Answer to Big Pharma

Bigger generics companies aren't just the generic sector's problem. Giants such as the new Teva will present more formidable challenges to innovators, not just in patent wars but also with proprietary launches, and for a share of drug consumption in developing markets.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts